SCHEMBL3958728

SCHEMBL3958728

CC(C)C(NCC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.42
CTSS P25774 2/20 0.42
CYP2D6 P10635 1/20 0.41
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
TSHR P16473 2/20 0.37
ALOX15 P16050 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
APP P05067 1/20 0.34
PTPRC P08575 2/20 0.34
PREP P48147 1/20 0.34
SDCBP O00560 1/20 0.34
SDC2 P34741 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16894118 1.00 CTSK (0.42) CTSKCTSSCYP2D6CA1CA2
SCHEMBL4372563 1.00 CTSK (0.42) CTSKCTSSCYP2D6CA1CA2
SCHEMBL12466119 0.86 CTSS (0.47) CTSKCTSSCYP2D6KMT2AMEN1
SCHEMBL1128239 0.86 CTSS (0.47) CTSKCTSSCYP2D6KMT2AMEN1
SCHEMBL3724961 0.84 CTSS (0.43) CTSKCTSSCYP2D6CA1CA2
SCHEMBL27821174 0.84 CTSS (0.43) CTSKCTSSCYP2D6CA1CA2
SCHEMBL16463894 0.84 CTSS (0.43) CTSKCTSSCYP2D6CA1CA2
SCHEMBL7437694 0.84 CA12 (0.42) CTSKCTSSCYP2D6CA1CA2
SCHEMBL7437701 0.84 CA12 (0.42) CTSKCTSSCYP2D6CA1CA2
SCHEMBL7438400 0.84 CA12 (0.42) CTSKCTSSCYP2D6CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084794-B2 Controlled cyclization of peptoids to form chiral diketopiperazines TRIAD NATIONAL SECURITY, LLC (US) 2021-08-10 US disclosed
US-20200131140-A1 CONTROLLED CYCLIZATION OF PEPTOIDS TO FORM CHIRAL DIKETOPIPERAZINES TRIAD NATIONAL SECURITY, LLC (US) 2020-04-30 US disclosed
EP-1753744-B1 PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2009-07-08 EP disclosed
US-7358258-B2 Prodrugs of an ERK protein kinase inhibitor VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-04-15 US disclosed
EP-1753744-A1 PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2007-02-21 EP disclosed
US-20060058318-A1 Prodrugs of an ERK protein kinase inhibitor VERTEX PHARMACEUTICALS INCORPORATED 2006-03-16 US disclosed
WO-2005113546-A1 PRODRUGS OF PYRROLYLPYRIMIDINE ERK PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS, INCORPORATED (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058318-A1 Prodrugs of an ERK protein kinase inhibitor MAP3K20, MAP3K1, MAP3K2 CTSK 994/4885CTSS 1705/4885CYP2D6 627/4885
US-11084794-B2 Controlled cyclization of peptoids to form chiral diketopiperazines NPPA, NPEPPS, RRP15 CTSK 1090/4885CTSS 643/4885CYP2D6 947/4885
US-20200131140-A1 CONTROLLED CYCLIZATION OF PEPTOIDS TO FORM CHIRAL DIKETOPIPERAZINES NPPA, NPEPPS, RRP15 CTSK 1090/4885CTSS 643/4885CYP2D6 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.